FDA grants fast track designation to sacituzumab govitecan for neoadjuvant/adjuvant metastatic urothelial cancer

Sacituzumab govitecan (an antibody-drug conjugate comprising hRS7, a humanised antibody, and SN-38 which is the active metabolite of irinotecan) is currently being evaluated in the Phase 2 TROPHY U-01 study of patients with this condition.


Biospace Inc.